Raltegravir: The first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium

Annals of the New York Academy of Sciences

Volumn 1222, Issue 1, 2011, Pages 83-89

  Nguyen, Bach Yen T ^a   Isaacs, Robin D ^a   Teppler, Hedy ^a   Leavitt, Randi Y ^a   Sklar, Peter ^a   Iwamoto, Marian ^a   Wenning, Larissa A ^a   Miller, Michael D ^a   Chen, Joshua ^a   Kemp, Ramon ^a   Xu, Wei ^a   Fromtling, Robert A ^a   Vacca, Joseph P ^a   Young, Steven D ^a   Rowley, Michael ^a   Lower, Michael W ^a   Gottesdiener, Keith M ^a   Hazuda, Daria J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

AIDS; HIV 1; Integrase inhibitor; Raltegravir

Indexed keywords

ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; INTEGRASE; LAMIVUDINE; MIDAZOLAM; PLACEBO; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; TENOFOVIR; TIPRANAVIR;

ARTICLE; DEPRESSION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROLOGIC DISEASE; NONHUMAN; SIDE EFFECT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79952834794     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.05972.x     Document Type: Article

References (35)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). AIDS epidemic update, December 2009. Available at: Accessed December 13, 2010.
2. Hammer, S.M., J.J. Eron, P. Reiss, et al 2008. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA 300: 555-570.
3. Mocroft, A., B. Ledergerber, C. Katlama, et al 2003. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22-29.
4. Palella, F.J., K.M. Delaney, A.C. Moorman, et al 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338: 853-860.
5. Little, S.J., S. Holte, J.-P. Routy, et al 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347: 385-394.
6. Weinstock, H.S., I. Zaidi, W. Heneine, et al 2004. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J. Infect. Dis. 189: 2174-2180.
7. Wensing, A.M.J., D.A. van de Vijver, G. Angarano, et al 2005. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect. Dis. 192: 958-966.
8. Shet, A., L. Berry, H. Mohri, et al 2006. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J. Acquir. Immune Defic. Syndr. 41: 439-446.
9. Grant, R.M., F.M. Hecht, M. Warmerdam, et al 2002. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288: 181-188.
10. Simon, V., J. Vanderhoeven, A. Hurley, et al 2002. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 16: 1511-1519.
11. Brenner, B., J.-P. Routy, Y. Quan, et al 2004. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 18: 1653-1660.
12. Brenner, B.G., J.-P. Routy, M. Petrella, et al 2002. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J. Virol. 76: 1753-1761.
13. Novak, R.M., L. Chen, R.D. MacArthur, J.D. Baxter, et al 2005. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin. Infect. Dis. 40: 468-474.
14. Violin, M., A. Cozzi-Lepri, R. Velleca, et al 2004. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 18: 227-235.
15. Richman, D.D., S.C. Morton, T. Wrin, et al 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS 18: 1393-1401.
16. Hare, S., S.S. Gupta, E. Valkov, et al 2010. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464: 232-236.
17. Espeseth, A.S., P. Felock, A. Wolfe, et al 2000. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. 97: 11244-11249.
18. Grobler, J.A., K. Stillmock, B. Hu, et al 2002. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. 99: 6661-6666.
19. Merck & Co., Inc. 2008. ISENTRESS (raltegravir tablets) Prescribing Information.
20. Iwamoto, M., L.A. Wenning, A.S. Petry, et al 2008. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin. Pharmacol. Ther. 83: 293-299.
21. Kassahun, K., I. McIntosh, D. Cui, et al 2007. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 35: 1657-1663.
22. Iwamoto, M., W.D. Hanley, A.S. Petry, et al 2009. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob. Agents Chemother. 53: 1747-1752.
23. Iwamoto, M., K. Kassahun, M.D. Troyer, et al 2008. Lack of pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J. Clin. Pharmacol. 48: 209-214.
24. Iwamoto, M., L.A. Wenning, A.S. Petry, et al 2008. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob. Agents Chemother. 52: 4338-4343.
25. Iwamoto, M., L.A. Wenning, G.C. Mistry, et al 2008. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin. Infect. Dis. 47: 137-140.
26. Hanley, W.D., L.A. Wenning, A. Moreau, et al 2009. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob. Agents Chemother. 53: 2752-2755.
27. Wenning, L.A., E.J. Friedman, J.T. Kost, et al 2008. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob. Agents Chemother. 52: 3253-3258.
28. Anderson, M.S., T.N. Kakuda, W. Hanley, et al 2008. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob. Agents Chemother. 52: 4228-4232.
29. Wenning, L.A., W.D. Hanley, D.M. Brainard, et al 2009. Effect of rifampin, a potent inducer of drug metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob. Agents Chemother. 53: 2852-2856.
30. Lennox, J.L., E. DeJesus, A. Lazzarin, et al 2009. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374: 796-806.
31. Lennox, J.L., E. DeJesus, D.S. Berger, et al 2010. Raltegravir-based compared to efavirenz-based regimens in treatment-naive HIV-1 infected patients: efficacy, durability, subgroup, safety, and metabolic analyses through 96 weeks of follow-up. J. Acquir. Immune Defic. Syndr. 55: 39-48.
32. Steigbigel, R.T., D.A. Cooper, P.N. Kumar, et al 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359: 339-354.
33. Cooper, D.A., R.T. Steigbigel, J.M. Gatell, et al 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359: 355-365.
34. Steigbigel, R.T., D.A. Cooper, H. Teppler, et al 2010. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin. Infect. Dis. 50: 605-612.
35. Rockstroh, J., H. Teppler, J. Zhao, et al 2010. Hepatic safety & efficacy of raltegravir in patients coinfected with HIV and hepatitis B (HBV) and/or C (HCV) virus. Presented at 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 2010 [Abstract Q-125.